Almost three years ago I wrote Has AI Changed the Course of Drug Development?. The post was cautiously skeptical. AlphaFold was the headline. BenevolentAI had just flopped a Phase 2a in atopic dermatitis. Verge Genomics’ VRG50635 was about to enter the clinic. I argued that data quality was the real bottleneck, not algorithms.
Time to revisit that.
I now lead epigenomics bioinformatics at AstraZeneca and I use Claude Code daily.